会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • CEREBRAL BIOPOTENTIAL ANALYSIS SYSTEM AND METHOD
    • 系统和方法分析生物电势脑
    • EP0764001B1
    • 2003-05-14
    • EP95922265.4
    • 1995-06-08
    • Aspect Medical Systems, Inc.
    • CHAMOUN, Nassib, G.SIGL, Jeffrey, C.SMITH, Charles, P.
    • A61B5/04G06F17/00
    • A61B5/048A61B5/16A61B5/4821A61B5/725A61B5/7253A61B5/7257G06F19/00G16H15/00
    • Disclosed is a system and method to derive a diagnostic index indicative of a selected cerebral phenomena which obtains 19 unipolar EEG signals from regions of interest on both the left and right hemispheres of a subject's brain. The system uses high-gain, low-noise amplifiers to maximize the dynamic range for low energy wave components of the signals. Band-pass filtering is used to reduce noise and to avoid aliasing. The system applies commonly used digital signal processing (DSP) techniques to digitize, to low-pass filter (100 Hz), and to decimate the signals. Power spectral, bispectral, and higher-order spectral processing is then performed. In a preferred embodiment, the system divides the most recent 63 seconds of digitized EEG data from each lead into 60 4-second intervals, each with 3 seconds of overlap with the previous interval. For a selected set of derived leads, the system produces auto power spectrum, autobispectrum, and auto higher-order spectrum variables, by using either a Fast Fourier Transform (FFT) based approach or a parametric approach. Any pair of leads can be combined to compute cross power spectrum, cross bispectrum, and cross higher-order spectrum variables. The spectral values are separated into bins and a value representative of the bin is selected or computed and then each value is multiplied by a predetermined coefficient. The resulting products are summed to arrive at the diagnostic index.
    • 5. 发明公开
    • CEREBRAL BIOPOTENTIAL ANALYSIS SYSTEM AND METHOD
    • FOR GEHIRNBIOPOTENTIAL分析系统和方法。
    • EP0468999A1
    • 1992-02-05
    • EP90905998.0
    • 1990-03-13
    • ASPECT MEDICAL SYSTEMS, INC.
    • CHAMOUN, Nassib, G.
    • A61B5G01R23G06F17G06K9
    • A61B5/4821A61B5/048A61B5/1106A61B5/16A61B5/6814A61B5/7257A61B2505/05G06F19/00G06K9/00523
    • Disclosed is a real time cerebral diagnostic apparatus and method for quantitatively evaluating, in a noninvasive manner, cerebral phenomena such as the depth and adequacy of anesthesia pain responses during surgical stress, acute cerebral ischemia, level of consciousness, degree of intoxication and ongoing normal and abnormal cognitive processes. A suitable electrode and amplifier system is used to obtain high resolution biopotentials from the regions of interest. Surface electroencephalographic (EEG) signals are filtered to allow the acquisition of frequencies between 2 and 500 Hz, then digitized and transmitted over a high speed serial line to a host computer where a 32 second long signal is divided into 128 consecutive 0.25 second intervals. Digital EEG data from unipolar leads is normalized and the dynamic phase and density relations within the signal are then characterized by estimating the third-order autocorrelation function or autobispectrum using either a frequency domain, or parametric approach. Paired EEG data from corresponding left and right hemisphere leads is used to characterize the dynamic phase and density relations between hemispheres by estimating the third order crosscorrelation function or crossbispectrum using either frequency domain or parametric techniques. Under certain specific filtering circumstances the power spectrum and crosspower spectrum are also computed. A reference clinical database is used to identify frequency pairs most sensitive to particular interventions or diagnostic states of interest. The values at these frequency pairs are then extracted from the patient's autobicoherence, autobispectral density, autobiphase, crossbicoherence, crossbispectral density, and crossbiphase arrays. The ensemble of values for the particular diagnostic determination is used to compute an index which serves as the diagnostic criterion by which the patient's state is judged. Any diagnostic index can be continuously displayed on a graphics terminal for real-time diagnostic monitoring or can be sent to a hard copy device to generate reports for the medical record.
    • 7. 发明授权
    • CARDIAC BIOPOTENTIAL ANALYSIS SYSTEM AND METHOD
    • 心脏生物分析系统与方法
    • EP0489010B1
    • 1998-11-18
    • EP90905061.9
    • 1990-03-13
    • ASPECT MEDICAL SYSTEMS, INC.
    • CHAMOUN, Nassib, G.
    • G06F17/18
    • A61B5/044A61B5/0452A61B5/04525A61B5/0464A61B5/413A61B5/7257A61B5/7275G06F19/00
    • Disclosed is a cardiac biopotential analysis system and method for detecting and quantifying in a noninvasive manner nonlinear dynamic patterns of depolarization and repolarization on a beat to beat basis in real time using bispectral analysis. A suitable body surface electrode acquires the signal from a region of interest. The signal is then amplified, digitized, and transmitted to a host microcomputer where an arrhythmia-free QRST complex is chosen interactively. Using standard cross-correlation methods a suitable number of complexes are extracted from the record. The extracted complexes are used to compute bispectral parameters using a frequency domain or a parametric based approach. A reference clinical database is used to identify frequency pairs most sensitive to particular interventions or diagnostic states of interest. The values at these frequency pairs are then extracted from the patient's bispectral arrays. The ensemble of values for the particular diagnostic determination under consideration is used to compute a single value index which serves as the diagnostic criterion by which the patient's state is judged. In this way the quantification of nonlinear dynamic properties of the frequency structure of the QRST yields information about the presence and extent of coronary artery disease (CAD), myocardial ischemia, cardiac electrical stability, risk of malignant ventricular arrhydthmia, site(s) of origin of malignant arrhythmias, extent of malignancy of arrhythmias, degree of antiarrhythmic drug efficacy, neural and humoral inputs to the heart, pump function/ejection fraction, and ongoing organ rejection in cardiac transplant patients.